Study on the Diagnosis and Management of CLL in Italy by GIMEMA

Overview

retrospective and prospective multicenter observational clinical and biological data collection from all patients with newly diagnosed CLL, SLL or MBL. retrospective cohort: all cases with a diagnosis between January 1st 2010 and August 31th 2021. prospective cohort: all patients with a diagnosis between September 1st 2021 and September 1st 2025.

Full Title of Study: “Observational Study on the Diagnosis and Management of Chronic Lymphocytic Leukemia (CLL) in Italy by Gruppo Italiano Malattie EMatologiche Dell’Adulto (GIMEMA)”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 2026

Detailed Description

This is a retrospective and prospective multicenter observational study designed by the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA). The study consists of clinical and biological data collection from all patients with newly diagnosed CLL, SLL or MBL (according to the WHO 2007 and 2018 diagnostic criteria). The retrospective part aims at including all cases followed at participating centers with a diagnosis between January 1st 2010 and August 31th 2021 (planned study initiation), while the prospective part will include all patients with a documented diagnosis of CLL, SLL or MBL between September 1st 2021 and September 1st 2025 by the first immunophenotypic/histological evaluation. The data is collected through electronic case report form accessible by the participating centers on a dedicated platform.

Clinical Trial Outcome Measures

Primary Measures

  • Describe the diagnosis and management of CLL patients
    • Time Frame: at 1 year for the prospective cohort and at 4 years for the retrospective cohort
    • evaluation of CLL management in terms of time to first treatment

Participating in This Clinical Trial

Inclusion Criteria

1. Age ≥18 years at diagnosis 2. One of the following diagnoses that meet the international diagnostic criteria (iwCLL2018 and WHO2017) 1. Chronic lymphocytic leukemia (CLL) 2. Small lymphocytic lymphoma (SLL) 3. CLL-like monoclonal B-cell lymphocytosis (MBL) 3. Retrospective cohort: CLL/SLL/MBL diagnosis between January 1st 2010 and August 31th 2021. 4. Prospective cohort: CLL/SLL/MBL diagnosis between September 1st 2021 and September 1st, 2025. 5. Signed written informed consent according to ICH/EU/GCP and national local laws (if applicable) Exclusion Criteria:

  • – -

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Gruppo Italiano Malattie EMatologiche dell’Adulto
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Paola Fazi, 0670390528, p.fazi@gimema.it

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.